Clinical Trials Logo

Advanced Malignant Tumor clinical trials

View clinical trials related to Advanced Malignant Tumor.

Filter by:

NCT ID: NCT04975204 Recruiting - Clinical trials for Advanced Malignant Tumor

A Clinical Trial of TQB3909 Tablets in Subjects With Advanced Malignant Tumors

Start date: February 18, 2022
Phase: Phase 1
Study type: Interventional

TQB3909 is an inhibitor targeting at B-cell lymphoma (BCL)-2 protein. By binding to BCL-2 protein, TQB3909 releases Pro apoptotic proteins such as BCL-2-Anatagonist/Killer 1(BAK), BCL-2 associated X (BAX) protein and BCL-2 associated death (BAD) protein, promotes the release of cytochrome c from mitochondria, phosphatidylserine eversion, stimulates caspase 3 / 7 activity and caspase 3 / 9 cleavage, and induces apoptosis.

NCT ID: NCT04954456 Recruiting - Clinical trials for Advanced Malignant Tumor

A Study of Bispecific Antibody QLS31901 in Patients With Advanced or Metastatic Malignancies

Start date: June 2, 2021
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open label, non-randomised, dose-escalation single agent study with expansion cohorts for dose confirmation/safety and preliminary efficacy of QLS31901 in advanced or metastatic malignancies

NCT ID: NCT04739111 Recruiting - Clinical trials for Advanced Malignant Tumor

An Exploratory Clinical Study of LDP Combined With CDP1 in Patients With Advanced Malignant Tumor

Start date: January 29, 2021
Phase: Phase 1
Study type: Interventional

This is an exploratory clinical study of Human Anti-PD-L1 Monoclonal Antibody Injection (LDP) combined with Recombinant Anti-EGFR Human Mouse Chimeric Monoclonal Antibody Injection (CDP1) in patients with advanced malignant tumor.

NCT ID: NCT04412564 Recruiting - Clinical trials for Advanced Malignant Tumor

A Study of TQ-B3101 Capsules in Subjects With Advanced Malignant Tumor

Start date: August 5, 2020
Phase: Phase 2
Study type: Interventional

The objective of this study is to evaluate efficacy and safety of TQ-B3101 in subjects with advanced malignant tumor.

NCT ID: NCT04326829 Recruiting - Clinical trials for Advanced Malignant Tumor

QL1604 Monotherapy for dMMR or MSI-H Advanced Solid Tumors

Start date: July 8, 2020
Phase: Phase 2
Study type: Interventional

In this study, patients with previously-treated locally-advanced or metastatic mismatched repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal carcinoma (CRC) and other solid tumors will be treated with QL1604 monotherapy.

NCT ID: NCT04296994 Active, not recruiting - Clinical trials for Advanced Malignant Tumor

A Study of QL1706 in Subjects With Advanced Malignant Tumor

Start date: March 31, 2020
Phase: Phase 1
Study type: Interventional

This is an open-label, multicenter, Phase 1, ascending dose escalation study of QL1706 in subjects with advanced malignant tumor. The study will be conducted in 2 parts. Part 1 of the study will be a dose escalation evaluation to determine the maximum tolerated dose (MTD) and to establish a recommended Phase 2 dose (RP2D) of QL1706. This study purpose is to describe the safety and tolerability, to assess Pharmacokinetics (PK) and immunogenicity, and to preliminarily assess the anti-tumor activity of QL1706 in subjects with advanced malignant tumor. Part 2 of the study will further characterize the PK parameters for QL1706 in subjects with advanced malignant tumor.